Biogen Idec Hemophilia Therapeutic Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $124M

Biogen Idec Hemophilia Therapeutic General Information

Description

Developer of biopharmaceuticals for the treatment of patients with chronic hematologic disorders. The company involves in developing recombinant long-acting Fc fusion molecules to provide prolonged protection from bleeding.

Contact Information

Formerly Known As
Syntonix Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 133 Boston Post Road
  • Weston, MA 02493
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 133 Boston Post Road
  • Weston, MA 02493
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biogen Idec Hemophilia Therapeutic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Jan-2007 $124M Completed Generating Revenue
5. Later Stage VC (Series C) 18-Jan-2006 Completed Generating Revenue
4. Later Stage VC 21-Sep-2005 Completed Generating Revenue
3. Debt - General 14-May-2004 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series B) 05-Apr-2002 $35.8M $50M Completed Startup
1. Early Stage VC (Series A) 01-Jan-2000 $14.2M $14.2M Completed Startup
To view Biogen Idec Hemophilia Therapeutic’s complete valuation and funding history, request access »

Biogen Idec Hemophilia Therapeutic Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Acquirer Systems Corporation Minority
Alta Partners Venture Capital Minority
BancBoston Ventures Venture Capital Minority
Bank of America Investment Bank Minority
Bay City Capital Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Biogen Idec Hemophilia Therapeutic FAQs

  • When was Biogen Idec Hemophilia Therapeutic founded?

    Biogen Idec Hemophilia Therapeutic was founded in 1997.

  • Where is Biogen Idec Hemophilia Therapeutic headquartered?

    Biogen Idec Hemophilia Therapeutic is headquartered in Weston, MA.

  • What industry is Biogen Idec Hemophilia Therapeutic in?

    Biogen Idec Hemophilia Therapeutic’s primary industry is Drug Discovery.

  • Is Biogen Idec Hemophilia Therapeutic a private or public company?

    Biogen Idec Hemophilia Therapeutic is a Private company.

  • What is the current valuation of Biogen Idec Hemophilia Therapeutic?

    The current valuation of Biogen Idec Hemophilia Therapeutic is .

  • What is Biogen Idec Hemophilia Therapeutic’s current revenue?

    The current revenue for Biogen Idec Hemophilia Therapeutic is .

  • How much funding has Biogen Idec Hemophilia Therapeutic raised over time?

    Biogen Idec Hemophilia Therapeutic has raised $72.3M.

  • Who are Biogen Idec Hemophilia Therapeutic’s investors?

    Acquirer Systems, Alta Partners, BancBoston Ventures, Bank of America, and Bay City Capital are 5 of 17 investors who have invested in Biogen Idec Hemophilia Therapeutic.

  • When was Biogen Idec Hemophilia Therapeutic acquired?

    Biogen Idec Hemophilia Therapeutic was acquired on 01-Jan-2007.

  • Who acquired Biogen Idec Hemophilia Therapeutic?

    Biogen Idec Hemophilia Therapeutic was acquired by Biogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process